Scottish biotech Trogenix raises $95M as brain cancer program nears clinic

Less than a year after leaving stealth mode, Trogenix has raised $95 million in a Series A round aimed at advancing its “Trojan horse” approach to treating cancer, starting with its lead program for glioblastoma.

The fundraise, which was backed by new investors including Eli Lilly, means the Scottish biotech should be able to dose the first glioblastoma patient with its viral immunotherapy candidate, called TGX-007, in the first quarter of 2026, according to a Monday release.